X-ray crystal structure of bone marrow kinase in the X chromosome: A Tec family kinase

Chemical Biology and Drug Design

Volumn 78, Issue 5, 2011, Pages 739-748

  Muckelbauer, Jodi ^a   Sack, John S ^a   Ahmed, Nazia ^a   Burke, James ^a   Chang, Chiehying Y ^a   Gao, Mian ^a   Tino, Joseph ^a   Xie, Dianlin ^a   Tebben, Andrew J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Dasatinib; Kinase inhibitor; PP2; Tyrosine kinase; X ray protein crystallography

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ABELSON KINASE; ADENOSINE TRIPHOSPHATE; BONE MARROW KINASE IN THE X CHROMOSOME; BRUTON TYROSINE KINASE; DASATINIB; INTERLEUKIN 2; PROTEIN KINASE; PROTEIN KINASE LYN; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME STRUCTURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN MOTIF; X RAY;

BINDING SITES; CHROMOSOMES, HUMAN, X; CRYSTALLOGRAPHY, X-RAY; HUMANS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES;

EID: 80054117850     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01230.x     Document Type: Article

References (38)

1. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV et al. (2007) Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem Med Chem;2:58-61.
2. Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, Takai T, Kodama T, Morio T, Geha RS, Kitamura D, Kurosaki T, Ellmeier W, Takayanagi H (2008) Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell;132:794-806.
3. Brunner C, Müller B, Wirth T (2005) Bruton's tyrosine kinase is involved in innate and adaptive immunity. Histol Histopathol;20:945-955.
4. Kosaka Y, Felices M, Berg LJ (2006) Itk and Th2 responses: action but no reaction. Trends Immunol;27:453-460.
5. Lin TA, McIntyre KW, Das J, Liu C, O'Day KD, Penhallow B, Hung CY et al. (2004) Selective Itk inhibitors block T-cell activation and murine lung inflammation. Biochemistry;43:11056-11062.
6. Weil D, Power MA, Smith SI, Li CL (1997) Predominant expression of muring Bmx tyrosine kinase in the granulo-monocytic lineage. Blood;90:4332-4340.
7. Ekman N, Lymboussaki A, Västrik I, Sarvas K, Kaipainen A, Alitalo K (1997) BMX tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. Circulation;96:1729-1732.
8. Zhang R, Xu Y, Ekman N, Wu Z, Wu J, Alitalo K, Min W (2003) Etk/Bmx transactivates vascular endothelial growthfactor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem;278:51267-51276.
9. Paavonen K, Ekman N, Wirzenius M, Rajantie I, Poutanen M, Alitalo K (2004) Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing. Mol Biol Cell;15:4226-4233.
10. He Y, Luo Y, Tang S, Rajantie I, Salven P, Heil M, Zhang R et al. (2006) Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogeneses. J Clin Invest;116:2344-2355.
11. Ding C, Cicuttini F, Li J, Jones G (2009) Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. Expert Opin Investig Drugs;18:1457-1466.
12. Semaan N, Alsaleh G, Gottenberg JE, Wachsmann D, Sibilia J (2008) Etk/Bmx, a Btk family tyrosine kinase, and Mal contribute to the cross-talk between MyD88 and FAK pathways. J Immunol;180:3485-3491.
13. Dai B, Kim O, Xie Y, Guo Z, Xu K, Wang B, Kong X et al. (2006) Tyrosine kinase Etk/Bmx is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res;66:8058-8064.
14. Paz K, Brennan LA, Iacolina M, Doody J, Hadari YR, Zhu Z (2005) Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Mol Cancer Ther;4:1801-1809.
15. Lowell CA, Soriano P (1996) Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Genes Dev;10:1845-1857.
16. Takesono A, Finkelstein LD, Schwartzberg PL (2002) Beyond calcium: new signaling pathways for Tec family kinases. J Cell Sci;115:3039-3048.
17. Marcotte DJ, Liu Y-T, Arduini RM, Hession CA, Miatkowski K, Wildes CP, Cullen PF, Hong V, Hopkins BT, Mertsching E, Jenkins TJ, Romanowski MJ, Baker DP, Silvian LF (2010) Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci;19:429-439.
18. DiPaolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RAD et al. (2011) Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol;7:41-50.
19. Kuglstatter A, Wong A, Tsing S, Lee SW, Lou Y, Villaseñor AG, Bradshaw JM, Shaw D, Barnett JW, Browner MF (2011) Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Sci;20:428-436.
20. Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. PNAS;104:13283-13288.
21. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Köcher T, Superti-Furga G (2007) Chemical proteomic profiles of the Bcr-Abl inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood;110:4055-4063.
22. Hantschel O, Rix U, Superti-Furga G (2008) Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma;49:615-619.
23. Kabsch W (2010) XDS. Acta Crystallogr D Biol Crystallogr;66:125-132.
24. Read RJ (2001) Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr;57:1373-1382.
25. Mao C, Zhou M, Uckun FM (2001) Crystal Structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of x-linked agammaglobulinemia. J Biol Chem;276:41435-41443.
26. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr;60:2126-2132.
27. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods in enzymology, Volume 276. In: Carter CW Jr, Sweet RM, editors. Macromolecular Crystallography, Part A. New York: Academic Press; p. 307-326.
28. Rawlingss DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM, Fluckiger AC, Witte ON, Kinet JP (1996) Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science;271:822-825.
29. Krissinel E, Henrick K (2004) Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr;60:2256-2268.
30. Liao J-L (2007) Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem;50:409-424.
31. Liu Y, Gray NS (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol;2:358-364.
32. Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FYF, Borzilleri R, Lombardo LJ, Xie D, Zhang Y, Klei HE (2006) The structure of dasatinib (BMS-354825) bound to activated Abl kinase domain elucidates its inhibitory activity against imatinib-resistant Abl mutants. Cancer Res;66:5790-5797.
33. Williams NK, Lucet IS, Klinken SP, Ingley E, Rossjohn J (2009) Crystal structures of the Lyn protein tyrosine kinase domain in its apo- and inhibitor-bound state. J Biol Chem;284:284-291.
34. Getlik M, Grütter C, Simard JR, Klüter S, Rabiller M, Rode HB, Robubi A, Rauh D (2009) Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J Med Chem;52:3915-3926.
35. Muratore KE, Seeliger MA, Wang Z, Fomina D, Neiswinger J, Havranek JJ, Baker D, Kuriyan J, Cole PA (2009) Comparative analysis of mutant tyrosine kinase chemical rescue. Biochemistry;48:3378-3386.
36. Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM, Zhao H, Morgenstern KA (1999) Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure;7:651-661.
37. Kutach AK, Villaseñor AG, Lam D, Belunis C, Janson C, Lok S, Hong L-N, Liu C-M, Deval J, Novak TJ, Barnett JW, Chu W, Shaw D, Kuglstatter A (2010) Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation. Chem Biol Drug Des;76:154-163.
38. Brown K, Long JM, Vial SCM, Dedi N, Dunster NJ, Renwick SB, Tanner AJ, Frantz JD, Fleming MA, Cheetham GMT (2004) Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors. J Biol Chem;279:18727-18732.